BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Li CZ, Hu JJ, Xue JY, Yin W, Liu YY, Fan WH, Xu H, Liang XS. Viral infection parameters not nucleoside analogue itself correlates with host immunity in nucleoside analogue therapy for chronic hepatitis B. World J Gastroenterol 2014; 20(28): 9486-9496 [PMID: 25071343 DOI: 10.3748/wjg.v20.i28.9486]
URL: https://www.wjgnet.com/1007-9327/full/v20/i28/9486.htm
Number Citing Articles
1
Lauke L Boeijen, Michelle Spaan, André Boonstra. The Effects of Nucleoside/Nucleotide Analogues on Host Immune Cells: The Baseline for Future Immune Therapy for HBV?Antiviral Therapy 2020; 25(4): 181 doi: 10.3851/IMP3364
2
Zhi-Qiang Zou, Li Wang, Kai Wang, Ji-Guang Yu. Innate immune targets of hepatitis B virus infectionWorld Journal of Hepatology 2016; 8(17): 716-725 doi: 10.4254/wjh.v8.i17.716
3
Urbano Sbarigia, Talitha Vincken, Peter Wigfield, Mahmoud Hashim, Bart Heeg, Maarten Postma. A comparative network meta-analysis of standard of care treatments in treatment-naïve chronic hepatitis B patientsJournal of Comparative Effectiveness Research 2020; 9(15): 1051 doi: 10.2217/cer-2020-0068
4
Lai Wei, Jia-Horng Kao. Benefits of long-term therapy with nucleos(t)ide analogues in treatment-naïve patients with chronic hepatitis BCurrent Medical Research and Opinion 2017; 33(3): 495 doi: 10.1080/03007995.2016.1264932
5
A. Velay, H. Jeulin, M. Eschlimann, B. Malvé, F. Goehringer, M. Bensenane, J-P. Frippiat, P. Abraham, A. M. Ismail, J. M. Murray, C. Combet, F. Zoulim, J-P. Bronowicki, E. Schvoerer. Characterization of hepatitis B virus surface antigen variability and impact on HBs antigen clearance under nucleos(t)ide analogue therapyJournal of Viral Hepatitis 2016; 23(5): 387 doi: 10.1111/jvh.12498
6
Xinzhi Wang, Luyong Zhang, Zhenzhou Jiang. T-helper cell-mediated factors in drug-induced liver injuryJournal of Applied Toxicology 2015; 35(7): 695 doi: 10.1002/jat.3115
7
Hao Feng, Jie Yin, Ya-Ping Han, Xiao-Ying Zhou, Su Chen, Li Yang, Jin-Rui Yan, Guo-Xin Zhang. Sustained Changes of Treg and Th17 Cells During Interferon-α Therapy in Patients with Chronic Hepatitis BViral Immunology 2015; 28(8): 412 doi: 10.1089/vim.2015.0024
8
Tongjing Xing, Hongtao Xu, Lin Cao, Maocong Ye, Ferruccio Bonino. HBeAg Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Nucleos(t)ide Analog Treatment: A Systematic Review and Network Meta-AnalysisPLOS ONE 2017; 12(1): e0169444 doi: 10.1371/journal.pone.0169444
9
Y.R. Zhang, B. Li, C.X. Wang, N. Zhou, W. Qi, X.L. Li, L.Y. Wu, S.F. Wei, Y.D. Zhang. Influence of Treg cells and HBV genotype on sustained response and drug resistance in the treatment with nucleoside drugsBrazilian Journal of Medical and Biological Research 2017; 50(3) doi: 10.1590/1414-431x20165796
10
Nianqiu Liu, Bin Liu, Li Zhang, Hu Li, Zhiwei Chen, Aoran Luo, Min Chen, Mingli Peng, Wenwei Yin, Hong Ren, Peng Hu. Recovery of circulating CD56dim NK cells and the balance of Th17/Treg after nucleoside analog therapy in patients with chronic hepatitis B and low levels of HBsAgInternational Immunopharmacology 2018; 62: 59 doi: 10.1016/j.intimp.2018.06.043